Federica Di Nicolantonio

Molecular Biology · 2012–2014

A researcher in the Science corpus: 3 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Federica Di Nicolantonio trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. W. Kaelin (in Molecular Biology)

Papers from Federica Di Nicolantonio's perspective

Ordered by how strongly the researchers Federica Di Nicolantonio trusts endorse each paper. Same corpus, a different order for every researcher.

  1. The Protein Kinase Complement of the Human Genome (Science)
  2. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. (Journal of Clinical Oncology)
  3. The Concept of Synthetic Lethality in the Context of Anticancer Therapy (Nature Reviews. Cancer)
  4. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
  5. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. (Cancer Cell)
  6. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma (New England Journal of Medicine)
  7. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy (Science)
  8. Detection of mutations in EGFR in circulating lung-cancer cells. (New England Journal of Medicine)
  9. The Consensus Coding Sequences of Human Breast and Colorectal Cancers (Science)
  10. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)

Their papers